Novavax Pharmaceuticals (NVAX. O) took a short dive, widening its decline to 4 percent, as the Wall Street Journal reported that the company's COVID-19 vaccine is unlikely to be approved anytime soon.
诺瓦瓦克斯医药(NVAX.O)短线跳水,跌幅扩大至4%,华尔街日报报道称,该公司新冠疫苗不可能很快获批。
Novavax Pharmaceuticals (NVAX. O) rose 52% in intraday trading and closed up nearly 99% on Friday.
Novavax Pharmaceuticals (NVAX. O) expanded premarket gains to more than 110 percent as the company reached a multi-billion dollar partnership with Sanofi.
Novavax Pharmaceuticals (NVAX. O) rose sharply before the market, expanding its gains to 200%.
Novavax Pharmaceuticals (NVAX. O) narrowed its premarket gains to 146 percent, having previously risen 217 percent.
诺瓦瓦克斯医药(NVAX.O)盘前涨幅扩大至逾110%,公司与赛诺菲达成数十亿美元合作。